Appendix B: Sources of Evidence

Appendix B: Sources of Evidence

1. The following documentation and opinion was made available to the Committee:

a. Assessment Report

  • Assessment report 'The clinical effectiveness and cost effectiveness of Riluzole in the Treatment of Motor Neurone Disease' by Stewart, Sandercock, Bryan, Hyde, Fry- Smith, Burls.West Midlands Development & Evaluation Service, University of Birmingham

  • Update Assessment Report prepared by the West Midlands Development and Evaluation Service (The clinical effectiveness and cost-effectiveness of Riluzole for Motor Neurone Disease, August 2000)

b. Manufacturer/Sponsor submissions:

  • Aventis Pharma

c. Professional/Specialist Group, Patient/Carer Group and Trade Association submissions:

  • Association of British Neurologists & Royal College of Physicians

  • Association for Palliative Medicine of Great Britain and Ireland

  • Chartered Society of Physiotherapy

  • Motor Neurone Disease Association

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Speech and Language Therapists

d. External expert and patient advocate submissions:

  • Professor Pamela Shaw, Section of Neurology, Royal Hallamshire Hospital, Sheffield

  • Ms. Julia Johnson, Speech and Language Therapist, King's College Hospital

  • Mr. George Levvy, Chief Executive, MND Association

  • Mr. Chris Davies, Member of MND Association.